Inhibition of oncostatin M in osteoarthritic synovial fluid enhances GAG production in osteoarthritic cartilage repair by Beekhuizen, M. et al.
80 www.ecmjournal.org
M Beekhuizen et al.                                                                                    Inhibition of OSM enhances cartilage repairEuropean Cells and Materials Vol. 26  2013 (pages 80-90)                                                                       ISSN 1473-2262
Abstract
Mediators in the synovial fluid are thought to play a major 
role in osteoarthritic cartilage turnover. The purpose of the 
current study was to investigate the role of oncostatin M 
(OSM) in osteoarthritis (OA) by evaluating the presence of 
the cytokine and its receptors in the OA joint and interfering 
with its activity in synovial fluid co-cultured with cartilage 
explants. OSM levels were increased in the synovial fluid 
of osteoarthritic patients compared to healthy donors. 
Immunohistochemistry confirmed the presence of both 
the leukaemia inhibitory factor (LIF) and OSM receptors 
for OSM throughout the whole depth of osteoarthritic 
cartilage and synovial tissue, whereas in healthy cartilage 
their presence seemed more restricted to the superficial 
zone. Blocking OSM activity, using an activity inhibiting 
antibody, in 25 % osteoarthritic synovial fluid added to OA 
cartilage explant cultures increased glycosaminoglycan 
(GAG) content from 18.6 mg/g to 24.3 mg/g (P < 0.03) and 
total production from 7.0 mg/g to 11.9 mg/g (P < 0.003). 
However, OSM exogenously added to cartilage explant 
cultures reflecting low and high concentrations in the 
synovial fluid (5 and 50 pg/mL) did not affect cartilage 
matrix turnover, suggesting that factors present in the 
synovial fluid act in concert with OSM to inhibit GAG 
production. The current study indicates the potential to 
enhance cartilage repair in osteoarthritis by modulating 
the joint environment by interfering with OSM activity.
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Introduction
One of the key processes in osteoarthritis (OA) is loss 
of the articular cartilage extracellular matrix due to a 
shift of the balance between production and degradation. 
Increased synthetic activity is evident by clonal expansion 
of resident chondrocytes and increased intensity of the 
territorial matrix surrounding them. However, this cannot 
compensate for the generalised loss of proteoglycans 
in the extraterritorial matrix, leading to a net loss of 
cartilage matrix (Martel-Pelletier et al., 2008). Soluble 
factors secreted from cartilage, synovial tissue and bone 
are known to play a role in the turnover of cartilage 
matrix, and many have been shown to both increase 
cartilage degeneration and inhibit the production of the 
extracellular matrix, which has been documented most 
extensively for interleukin-1 (IL-1) and tumour necrosis 
factor-a (TNFα) (Fernandes et al., 2002; Goldring and 
Marcu, 2009; Goldring and Goldring, 2004; Martel-
Pelletier et al., 1999). Another soluble factor that may 
be important in affecting cartilage matrix integrity in OA 
is the pro-inflammatory cytokine oncostatin M (OSM). 
OSM, a cytokine from the interleukin-6 (IL-6) family, 
is secreted by osteoarthritic synovial tissue (Beekhuizen 
et al., 2011) and is found in rheumatoid synovial fluid 
(Hui et al., 1997). OSM is associated with multiple 
processes in the body, e.g. haematopoiesis, neural and 
liver development and cell proliferation (Miyajima et al., 
2000; Tanaka et al., 2003; Tanaka and Umesaki, 2003) 
and in rheumatoid arthritis (RA), OSM is associated with 
bone erosion, synovial inflammation and fibrosis, and 
cartilage degeneration (Sims and Walsh, 2010; Walker et 
al., 2010). The potential of OSM to degenerate cartilage 
and induce catabolic processes in chondrocytes was shown 
in different studies (Barksby et al., 2006; Durigova et 
al., 2011), although nothing is known about its effect 
on cartilage synthesis. In addition, OSM is known to 
synergise with catabolic cytokines such as IL-1 and 
TNFa in the induction of cartilage degeneration in vitro 
(Barksby et al., 2006; Catterall et al., 2001; Gilbert et al., 
2012; Hui et al., 2001; Hui et al., 2003). However, most 
pro-inflammatory cytokines, including OSM, have been 
demonstrated only at low levels in osteoarthritic synovial 
fluid (Hui et al., 1997; Manicourt et al., 2000; Okamoto et 
al., 1997; Rutgers et al., 2009), and it is not clear whether 
such interactions are relevant in OA-associated cartilage 
degeneration in vivo. Moreover, therapies targeting IL-1 
and TNFα were shown to be ineffective in inhibiting 
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osteoarthritic cartilage loss, in contrast to their application 
in rheumatoid arthritis.
 OSM signals through two different receptor complexes, 
the GP130/LIFRb (LIFR) or the GP130/OSMRb (OSMR) 
complex (Gearing et al., 1992; Mosley et al., 1996; 
Thoma et al., 1994). The OSMR was demonstrated in 
a chondrocyte cell line and in synovial fibroblasts. In 
addition, OSM signalling is mediated through the protein 
kinase R signalling pathway in bovine chondrocytes 
(Gilbert et al., 2012). Although both receptors for OSM 
have been shown in multiple tissues, e.g. liver and prostate 
with different expression in healthy and pathologic 
conditions (Royuela et al., 2004; Znoyko et al., 2005), the 
presence of the different receptors for OSM has not been 
studied in healthy or in osteoarthritic cartilage tissue in 
vivo (Rowan et al., 2001).
 The purpose of this study was to elucidate the role of 
OSM in OA and more specifically the effect of inhibiting 
OSM on cartilage integrity in OA. To this end, the levels 
of OSM in the synovial fluid of osteoarthritic patients were 
compared to healthy subjects, and the presence of receptors 
for OSM was evaluated in healthy and osteoarthritic joint 
tissue. Furthermore, the role of OSM in cartilage repair 
was studied by culture of OA cartilage explants with OA 
synovial fluid in the presence or absence of a blocking 
antibody against OSM. Finally, to determine whether 
OSM could directly affect cartilage repair, the effect of 
recombinant OSM on cartilage explants at concentrations 
found in OA synovial fluid was studied.
Materials and Methods
Harvesting of cartilage, synovial tissue and synovial 
fluid
Osteoarthritic cartilage was collected under sterile 
conditions from patients undergoing total knee arthroplasty 
for OA. Cartilage explants were harvested from the femoral 
condyles, cut into square pieces of approximately 1 x 1 mm 
and the wet weight was determined so glycosaminoglycan 
(GAG) release, content and production could be corrected 
for cartilage weight (Mastbergen et al., 2005). No 
difference was made between damaged or more intact 
cartilage, for histology, tissue analysis nor explant cultures. 
Only the almost completely denuded bone areas were 
not used. From each donor, 6 cartilage explants were 
fixed immediately in 4 % formaldehyde for histological 
evaluation and 6 were wet weighted and stored at -20 °C 
for biochemical analysis at t = 0. The rest of the explants 
were used for culturing or cell isolation.
 Osteoarthritic synovial fluid and synovial tissue 
was obtained during total knee arthroplasty, healthy 
synovial fluid and tissue were collected from post 
mortem donors within 24 h after death, only if the knee 
cartilage was macroscopically healthy. The synovial 
tissue was immediately fixed in 4 % formaldehyde for 
immunohistochemical analysis. Synovial fluid was stored 
at -80 °C.
 To obtain OA chondrocytes, articular cartilage was 
cut and digested in collagenase 0.15 % (Worthington, 
Lakewood, NJ, USA) overnight at 37 °C. Subsequently, 
the chondrocytes were seeded in a monolayer at a cell 
density of 5000 cells/cm2 and cultured in expansion 
medium containing Dulbecco’s Modified Eagle Medium 
(DMEM), 10 % foetal bovine serum (FBS), 1 % penicillin/
streptomycin (pen/strep) and 10 ng/mL basic fibroblast 
growth factor (bFGF; R&D Systems, Minneapolis, MN, 
USA). Chondrocytes were cultured until passage 2. 
Anonymous use of redundant tissue for research purposes 
is part of the standard treatment agreement with patients 
in our university hospital and according to the national 
guidelines ‘code of conduct for the proper secondary use 
of human tissue’ (van Diest, 2002).
Multiplex ELISA
The presence of OSM in synovial fluid was determined 
using multiplex ELISA, as part of a multiplex ELISA for 
several cytokines, as previous described (Beekhuizen et al., 
2011). Validation of the Multiplex ELISA was previously 
done by de Jager et al., showing excellent sensitivity and 
specificity (de Jager et al., 2005; de Jager et al., 2003). 
Synovial fluid was pre-treated with hyaluronidase for 
15 min at 37 °C. Samples were spun down in a X-column 
(Costar 8169; Corning Inc, Corning, NY, USA) and 
dissolved in 0.1375 % high performance ELISA buffer 
(HPE)-Tween-20. The pre-treated synovial fluid was 
incubated with the coupled beads. After incubation with 
the biotinylated antibodies, samples were incubated 
with streptavidin-phycoerythrin (PE). The samples were 
measured and analysed using the Bio-Plex suspension 
system (Bio-Rad Laboratories, Hercules, CA, USA). The 
concentration of OSM in the synovial fluid was calculated 
using the standard curve and is expressed as pg/mL.
(Immuno)histochemistry
For (immuno)histochemistry, the cartilage and synovial 
tissue explants were fixed overnight in 4 % formaldehyde, 
embedded in paraffin and cut into 5 µm sections. To 
evaluate the cartilage degeneration grade (Pritzker et 
al., 2006), a safranin-O and fast-green staining was used 
(Rosenberg, 1971). For LIFR staining (sc-659, C-19; Santa 
Cruz Biotechnologies, Santa Cruz, CA, USA), sections 
were incubated with polyclonal anti-rabbit LIFRb (both 
cartilage and synovial tissue; concentration 0.67 µg/
mL) for 1 h at room temperature (Royuela et al., 2004; 
Znoyko et al., 2005). The sections were incubated with 
anti-rabbit–horseradish peroxidase (HRP) (1.25 µg/mL; 
Dako, Glostrup, Denmark). Sections were developed 
by incubations with 3,3’diaminobenzidine (DAB) for 
5 min. For OSMR staining, sections were incubated with 
polyclonal anti-goat OSMRb (sc-8496, C-20; SantaCruz; 
for cartilage sections at 2.0 µg/mL and synovial tissue at 
4.0 µg/mL) overnight. Sections were incubated with anti-
goat-HRP (2.5 µg/mL, Dako) for 1 h. Finally, sections 
were developed by incubation with DAB. For the negative 
controls, adjacent sections of both healthy and osteoarthritic 
cartilage and synovial tissue were incubated with an isotype 
anti-rabbit IgG (Dako) for the LIFR or isotype anti-goat 
IgG (Santa Cruz Biotechnologies) for OSMR. As a positive 
control, human thymus sections were used.
 To quantify the LIFR and OSMR staining, the 
percentage of positive cells in both cartilage and synovial 
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tissue sections was determined using semi-automatic 
software (Leica Microsystems, Rijswijk, The Netherlands). 
The cells were counted with a grid distance of 17.6 µm. All 
sections were blinded and at least 100 cells were counted 
per slide. In total at least 5 healthy and 5 OA donors were 
used for both cartilage and synovial tissue. For the cartilage 
explants, only the positive cells in the middle and deep layer 
were counted, due to the loss of the superficial layer in OA 
cartilage explants. For synovial tissue, all cells throughout 
the entire tissue were counted.
Culture of cartilage explants in OA synovial fluid
To evaluate the effect of OSM present in synovial fluid on 
cartilage metabolism, the activity of OSM in OA synovial 
fluid was blocked with an activity-inhibiting antibody. For 
these experiments the synovial fluid from multiple (± 8) OA 
donors were pooled to obtain sufficient amounts of synovial 
fluid for a total culture period of 14 d. In total 3 different 
pooled synovial fluids were used, at OSM concentrations 
between 25 and 40 pg/mL. The pooled synovial fluid was 
aliquoted and stored at -80 °C until use. Cartilage explants 
from 5 different donors (n = 6 per donor/per condition) 
were cultured in the presence or absence of 25 % pooled 
OA synovial fluid, at a final OSM concentration of 6.25 or 
11.25 pg/mL (25 % OA synovial fluid dissolved in medium), 
in DMEM (Gibco BRL Life Technologies, Darmstadt, 
Germany) containing penicillin and streptomycin (Gibco), 
ascorbate-2-phosphate (Sigma-Aldrich, St Louis, MO, 
USA), Insulin Transferrin Selenium-X (ITS-X) (Gibco) 
and 50 mg/mL L-proline (Sigma) for 14 d. To block the 
effect of OSM, an activity-inhibiting antibody against OSM 
was used at a concentration of 10 µg/mL (MAB295; R&D, 
Minneapolis, MN, USA). Isotype IgG antibody (MAB002; 
R&D) and cultures with anti-OSM antibody only served 
as controls. The culture medium was renewed 3 times per 
week. For each medium change, fresh synovial fluid (25 %) 
and anti-OSM or isotype antibody was added to the culture 
medium. The supernatant was stored at -80 °C for further 
analysis. After 14 d of culture, one explant was fixed for 
histochemical analysis. The rest of the explants were stored 
at -20 °C for biochemical analysis.
Effect of OSM inhibition on PGE2 production by 
OSM stimulated OA chondrocytes
To assess whether the anti-OSM antibody was effectively 
blocking OSM activity, OA chondrocytes were cultured in 
the presence or absence of 2 ng/mL recombinant OSM, or 
10 µg/mL OSM activity-inhibiting antibody (anti-OSM). 
As a control, unstimulated cells and an isotype IgG were 
used. The OA chondrocytes were seeded in a density of 
42,000 cells per well for a total culture period of 3 d. After 
3 d, the conditioned medium was stored. The inhibiting 
effect of anti-OSM was determined using a prostaglandin 
E2 (PGE2) ELISA. In total 1 OA donor was used with 
n = 4 per condition.
PGE2 analysis
PGE2 concentration in the conditioned medium of OSM 
stimulated OA chondrocytes was determined using 
a competitive PGE2 ELISA (ENZO Life Sciences, 
Antwerpen, Belgium), according to the manufacturer’s 
protocol.
Culture of cartilage explants in the presence of 
recombinant OSM
OA cartilage explants from 4 different donors (n = 6 per 
donor/per condition) were cultured for 14 d in the presence 
or absence of recombinant OSM (295-OM; R&D) at 5 
and 50 pg/mL, representing the lowest and the average 
concentration of OSM found in OA synovial fluid. As a 
positive control a concentration of 10 ng/mL, previously 
shown to have an effect on cartilage metabolism (Durigova 
et al., 2008a; Durigova et al., 2008b), was also included. 
Culture medium was renewed 3 times a week and stored 
at -80 °C for further analysis. One explant was fixed for 
further histochemical analysis. The remaining explants 
(n = 5) were stored at -20 °C for biochemical analysis.
Biochemistry
GAG release and total GAG content was quantified using 
the dimethylmethylene-blue (DMMB) spectrophotometric 
analysis described by Farndale et al. (1986). Cartilage 
explants were digested in 400 mL 2 % papain (Sigma) 
in 50 mM phosphate buffer, 2 mM N-acetylcysteine, 
and 2 mM Na2-EDTA (pH 6.5) at 60 °C overnight. Two 
hundred mL of DMMB solution and 100 mL of medium 
sample or papain digest were mixed and absorbance read 
at 540 nm and 595 nm using a spectophotometer (Bio-
Rad Laboratories). As reference, chondroitin sulphate C 
(Sigma) was used. Calculation of GAG production was 
performed using the following formula:
Table 1. Results of LIFR and OSMR staining in osteoarthritic and healthy cartilage 
and synovial tissue.
Per condition 5 samples were scored using semi-automatic software. At least 100 cells 
were counted per section. Data is given in % ± SD of positive cells.
Healthy (% ± SD) Osteoarthritic (%± SD) P value
Cartilage
LIFR 73.0 ± 10.4 72.3 ± 21.9 1.00
OSMR 19.4 ± 16.5 24.4 ± 16.8 0.73
Synovial tissue
LIFR 71.2 ± 4.3 86.3 ± 9.0 * 0.04
OSMR 0 ± 0 10.3 ± 12.9 * 0.04
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   GAGproduction = (GAGcontent day 14 - GAGcontent day zero) + GAGcumulative release
given in mg GAG/g cartilage.
Statistical analysis
Data are expressed as mean ± SD. SPSS 16.0 software 
(SPSS Inc. Chicago, IL, USA) was used for the statistical 
analysis. The data was tested for normality and Gaussian 
distribution. A Student’s t-test was used to assess difference 
between the healthy and osteoarthritic synovial fluid 
samples. Univariate analysis of variance (ANOVA), with 
a randomised block design and a post-hoc Bonferroni 
was used to assess differences in the glycosaminoglycan 
parameters. Differences with a P-value less than 0.05 
were considered statistically significant. Differences in 
the percentage of receptor-positive cells in cartilage and 
synovial tissue scored after immunohistochemistry were 
evaluated by a Mann-Whitney U test.
Results
Presence of OSM in OA synovial fluid
In the OA synovial fluid samples OSM was detected in 
10 of the 32 samples (range 0-570 pg/mL; mean 39 pg/
mL), whereas in the healthy samples only one of the 23 
samples contained OSM (range 0-25 pg/mL; mean 1 pg/
mL; P < 0.001) (Fig. 1).
Presence of receptors for OSM in joint tissue
The LIFR was present throughout the entire cartilage 
depth in both osteoarthritic and healthy cartilage (Fig. 
2). In healthy cartilage, the OSMR was mainly expressed 
in chondrocytes in the superficial layer and some 
chondrocytes in the middle and deep layer. However, in 
osteoarthritic cartilage, positive chondrocytes were found 
throughout the entire cartilage (Fig. 3). As the superficial 
layer in OA cartilage was lost, only the middle and deep 
zones of healthy and OA tissues were quantified for the 
presence of LIF and OSM receptor-positive cells. No 
statistically significant difference between healthy and OA 
cartilage for LIFR nor OSMR staining was found (Table 1).
 Synovial tissue of both healthy and osteoarthritic joints 
expressed the LIFR (Fig. 4), with positive cells mainly 
expressed in the synovial tissue lining. The expression 
of LIFR in OA synovial tissue was slightly higher 
compared with healthy synovial tissue (P < 0.04; Table 
1). Furthermore, the OSMR was not expressed in any of 
the healthy synovial tissue donors (Fig. 4 and Table 1), 
whereas in the osteoarthritic synovial tissue multiple cells 
in the synovial lining expressed the OSMR (P < 0.04; Fig. 
4 and Table 1).
Effect of blocking OSM in synovial fluid on cartilage
To study the role of OSM in osteoarthritic cartilage 
degeneration, OA cartilage explants were cultured in the 
presence of OA synovial fluid (the OSM concentration in 
the pooled synovial fluids ranged between 30 and 40 pg/
mL; data not shown), in the presence or absence of an 
activity-inhibiting antibody against OSM (anti-OSM). 
Although addition of OA synovial fluid to cartilage 
explants for 14 d did not affect GAG content, release or 
production in cartilage explants (Fig. 5), blocking OSM in 
OA synovial fluid increased GAG content from 18.6 mg/g 
to 24.3 mg/g (P < 0.03) and production from 7.0 mg/g to 
11.9 mg/g (P < 0.003) in cartilage explants (Fig. 5a,c). 
Blocking OSM in synovial fluid did not have an effect on 
GAG release (Fig. 5b). Anti-OSM did not affect any of the 
turnover parameters in cartilage explants in the absence 
of synovial fluid. The effectiveness of the antibody was 
shown in OSM-stimulated OA chondrocytes, where the 
effect of recombinant OSM on PGE2 production was 
completely abrogated by the anti-OSM antibody but not by 
the isotype control (Fig. 5d; P < 0.001). There was a basal 
production of PGE2 by the OA chondrocytes as shown by 
the unstimulated control.
Effect of recombinant OSM on OA cartilage
The effect of OSM alone on OA cartilage explants was 
studied by addition of recombinant OSM to OA cartilage 
explants. Only at a supraphysiological concentration 
of 10 ng/mL, but not at 5 or 50 pg/mL, GAG content 
decreased and GAG release increased (Fig. 6a/b; P < 0.05 
and P < 0.001). No effect on total GAG production was 
noted irrespective of the concentration used (Fig. 6c).
Fig. 1. OSM concentration in healthy (n = 24) and 
osteoarthritic (n = 32) synovial fluid samples. In healthy 
synovial fluid OSM was detected in only one sample 
(1.5 ± 6.8 pg/mL). In osteoarthritic synovial fluids OSM 
was detected in 10 out of 32 samples (39.7 ± 108.0 pg/
mL; *P < 0.001). § = 24 samples, # = 22 samples.
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Discussion
The current study showed increased levels of OSM 
in osteoarthritic synovial fluid and expression of both 
receptors for OSM in cartilage and synovial tissue. 
Although the receptors were found both in healthy and OA 
joint tissue, their expression seemed to be more widespread 
in OA tissue. Addition of OA synovial fluid to cartilage 
explant cultures did not affect matrix turnover. However, 
when OSM was blocked in OA synovial fluid, cartilage 
repair was clearly enhanced. In contrast, recombinant OSM 
added to cartilage explants at the concentrations found in 
OA synovial fluid did not affect chondrocyte metabolism.
 The role of OSM in rheumatoid arthritis and joint 
tissues other than cartilage has been extensively studied 
(Cawston et al., 1998; Hui et al., 2005; Nowell et al., 2006; 
Walker et al., 2010). OSM in combination with IL-1 or 
TNFa induced bone destruction via the RANK/RANKL 
pathway (Hui et al., 2005). Moreover, OSM triggered 
angiogenesis and cell migration in synovial tissue (Fearon 
et al., 2006). These changes are also known to occur in 
OA in synovial tissue (Felson, 2006). In RA, however, the 
levels of the pro-inflammatory cytokines IL-1, TNFa and 
OSM are high, in contrast to OA where almost no IL-1 or 
TNFa is present. Possibly, this might cause the different 
effects of OSM in RA compared to OA.
 Receptors for OSM are found in multiple cell types 
in the joint, such as osteoblasts, synovial fibroblasts and 
chondrocytes, indicating that OSM could exert an effect 
on all tissues in the joint. Rowan et al. (2001) showed 
the presence of GP130/OSMRß complex, but failed to 
detect the GP130/LIFRß complex, in an immortalised 
chondrocyte cell line. Other studies showed the presence 
of the OSMR and LIFR in both osteoblasts (Allan et al., 
1990; Walker et al., 2010) and synovial fibroblasts (Nowell 
et al., 2006). However, OSM receptor expression in healthy 
and diseased joint tissue has never been reported before, let 
alone the existence of differences in expression between 
healthy and diseased tissue. Although OSM receptor 
expression was not evidently different in cartilage tissue, 
Fig. 2. Immunohistochemistry for LIFR in healthy (upper panels) and osteoarthritic cartilage (lower panels). LIFR 
is present in osteoarthritic cartilage throughout the entire cartilage (middle and right lower panels). In the healthy 
cartilage, only some cells in the superficial layer showed positive staining (middle and right upper panels). The left 
panels show the safranin-O staining of the healthy (upper left) and osteoarthritic cartilage (lower left). Positive cells 
stained brown by DAB and indicated by the arrow; scale bar represents 500 mm, or 40 mm (magnified right panels).
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in synovial tissue the expression of the receptors for OSM 
was up-regulated in osteoarthritic samples, in contrast 
to healthy tissue where almost no cells were positive. 
This indicates an increased expression of the OSMR in 
diseased joint tissue, which may further enhance the effects 
induced by OSM. In addition, the LIFR was upregulated 
in osteoarthritic synovial tissue.
 Studies have showed that gene activation through the 
LIFR and the OSMR are different. Whereas OSM normally 
signals through the LIFR and activates JAK/STAT 
transcriptional activators, OSM can also act via OSMR. 
However, the OSMR can also activate specific pathways 
through activation of the MAPK signalling cascade 
(Halfter et al., 1999; Mosley et al., 1996), suggesting that 
dependent on receptor expression, different responses, 
e.g. MMP activity and chondrocyte metabolism, could be 
generated in osteoarthritis. OSM is the only cytokine from 
the IL-6 family that can induce cartilage degeneration, 
albeit at non-physiologically high concentrations (Hui 
et al., 2000; Hui et al., 2003). This is most likely via the 
induction of matrix degrading proteases, e.g. MMPs and 
ADAMTS, which are known to be increased in OSM-
stimulated cartilage explants or chondrocyte cultures 
(Durigova et al., 2008a; Durigova et al., 2008b; Durigova 
et al., 2011; Gilbert et al., 2012). Although the proteases 
involved downstream of OSM signalling were not further 
identified in the current study, stimulation of GAG release 
by the addition of a high concentration of OSM is in line 
with previous data.
 In RA, OSM levels are high and in concert with 
high concentrations of IL-1 and TNFa known to induce 
degeneration and GAG release (Manicourt et al., 2000). 
The use of neutralising OSM antibodies in two different 
models of murine RA was shown to partially prevent 
Fig. 3. Immunohistochemistry for OSMR in healthy (upper panels) and osteoarthritic cartilage (lower panels). OSMR 
is present in osteoarthritic cartilage throughout the entire cartilage (middle and right lower panels).  In the healthy 
cartilage cells in the superficial layer showed positive staining and some cells in the middle/deep layer (middle and 
right upper panels). The left panels show the safranin-O staining of the healthy (upper left) and osteoarthritic cartilage 
(lower left). Positive cells stained brown by DAB and indicated by the arrow; scale bar represents 500 mm, or 40 mm 
(magnified right panels).
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cartilage destruction (Plater-Zyberk et al., 2001). In 
addition, blockers of several cytokines binding the GP130 
family of receptors, such as IL-6, are currently used in 
the clinic (Maini et al., 2006; Nishimoto et al., 2007). In 
particular, tocilizumab, a monoclonal antibody against the 
IL-6 receptor, was found to have a positive effect on disease 
symptoms and to decrease the levels of markers of bone 
and cartilage degeneration in patients with RA (Garnero 
et al., 2010; Hashimoto et al., 2011).
 Despite the clear degenerative effect of OSM at high 
levels, its mode of action in osteoarthritis seems to be 
somewhat different. Levels of OSM, but also of TNFa and 
IL-1 are low in OA synovial fluid (Vignon et al., 1993). 
Moreover, at the levels found in OA synovial fluid, OSM 
does not induce cartilage breakdown, which is in line with 
the observation that inhibition of the OSM present in OA 
synovial fluid does not inhibit GAG release. In contrast, the 
increased production and deposition of extracellular matrix 
found upon inhibition of OSM activity rather suggests an 
inhibitory effect of OSM on an anabolic factor(s) in the 
synovial fluid. In other studies, the precise role and effect of 
OSM on extracellular matrix production should be further 
investigated.
 As this is an artificial in vitro model with only cartilage 
explants, we cannot exclude that the culture method (e.g. 
culture medium with high concentration insulin, no bone 
or synovial tissue present) may have partly masked the 
effect of inhibiting OSM. Future in vivo experiments will 
show if inhibiting OSM could stop OA degeneration in a 
more challenging and less controlled environment.
 It should be borne in mind that in almost 70 % of the OA 
synovial fluid samples OSM was undetectable, and hence 
its role may be limited to those patients in which OSM 
is produced. The presence of OSM in some patients may 
suggest different (stages of) pathology. We have recently 
shown that OSM clusters with several other cytokines, such 
as IL-1b, IL-8 and IFNg, suggesting it is part of a common 
pathway (Beekhuizen et al., 2013), which should be further 
investigated. We observed, however, no association of 
OSM production with other aspects of pathology, such as 
synovial inflammation. However, we did not have access 
to the patient data and did not obtain synovial tissue of 
all OA patients, so we cannot state with certainty that this 
association did not exist. Still, as inhibition of these low 
concentrations already resulted in such clear effects on 
cartilage repair, it cannot be excluded that very low, but 
undetectable OSM levels were present in all donors and 
would still have resulted in increased matrix production 
upon inhibition. Even if this would not hold true, a 30 % 
reduction in OA disease morbidity would already have a 
huge impact on society in terms of disease burden. It is 
important to note that the synovial fluid could only be used 
at 25 %, due to its limited availability, suggesting that the 
enhancement of cartilage matrix production may have 
been even more pronounced with higher concentrations 
of synovial fluid.
Conclusions
This study shows that OSM plays a role in cartilage 
matrix turnover during osteoarthritis. By blocking OSM 
in the synovial fluid of OA patients, cartilage repair is 
improved in osteoarthritic cartilage. Supported by the lack 
of effect found for exogenously added OSM, these data 
indicate that OSM indirectly inhibits repair mechanisms in 
osteoarthritis. Moreover, the presence of receptors for OSM 
in both cartilage and synovial tissue suggests that blocking 
OSM could have an effect on multiple joint tissues and 
not just cartilage. The current study is one of the first that 
show that cartilage repair can be improved by altering the 
joint environment in osteoarthritis.
Fig. 4. Immunohistochemistry for LIFR and OSMR in healthy and osteoarthritic synovial tissue. LIFR is present 
in both healthy and osteoarthritic synovial tissue (left pictures). OSMR was abundantly expressed in osteoarthritic 
synovial tissue, however not in healthy synovial tissue (right pictures; positive cells stained brown by DAB and 
indicated by the arrow; scale bar represents 500 mm, or 20 mm in magnified panel).
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Fig. 5. Effect of blocking OSM in synovial fluid on osteoarthritic 
cartilage explants cultured for 14 d. Blocking OSM in osteoarthritic 
synovial fluid increased GAG content in cartilage (a; * P < 0.03) 
and increased GAG production (c; # P < 0.003), however, did not 
have an effect on GAG release (b). Addition of only synovial fluid 
did not have an effect on GAG content, release or production in 
osteoarthritic cartilage (mean ± SD of 5 different OA donors; 
5 explants per donor/condition in mg GAG/g cartilage). Anti-
OSM, at a concentration of 10 mg/mL, completely decreased the 
production of PGE2 induced by 2 ng/mL of recombinant OSM 
by OA chondrocytes (d; § P < 0.001; mean +/- SD of 1 donor; 
n = 4 per condition).
Fig. 6. Effect of recombinant OSM on osteoarthritic 
cartilage explants cultured for 14 d. At 10 ng/mL, 
recombinant OSM increased GAG release and decreased 
GAG content (a,b; * P < 0.05, # P < 0.001). However, 
no effect was seen at concentrations in the range of those 
found in OA synovial fluid (5 and 50 pg/mL). None 
of the concentrations of OSM had an effect on GAG 
production (c; mean +/- SD of 4 different OA donors; 5 
explants/donor per condition in mg GAG/g cartilage).
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Discussion with Reviewers
Reviewer I: How does a positive effect on GAG production 
and release in vitro equate to a positive effect on cartilage 
regeneration in vivo? Surely, cartilage regeneration depends 
on more than GAG production.
Authors: Our focus has been on GAG turnover as one 
of the major outcome parameters of cartilage repair, a 
commonly used readout parameter in cartilage research. 
We agree with the reviewer that there is more to cartilage 
repair than only GAG production. Collagen II production 
would also be very informative, but turnover of collagen 
is slow and hence differences in collagen content will 
be difficult to detect in biochemical analysis in such a 
short culture period. Whether any effect in vitro can be 
reproduced in vivo is always a matter of debate and we 
certainly agree that given the promising results in vitro, it 
would be interesting as a next step to investigate the effect 
of intra-articular anti-OSM in an experimental model of 
osteoarthritis in vivo.
Reviewer I: Does OA cartilage regenerate or repair?
Authors: The reviewer raises an important issue that 
possibly should also be raised in the cartilage community 
in general. According to the Biology online definition, 
regeneration is “The natural renewal of a structure, as of 
a lost tissue or part” and to the Oxford Dictionary “The 
formation of new animal or plant tissue”. As cartilage tissue 
is present before start of the culturing of the explants (see 
Fig. 2), the correct term should indeed be repair of the 
osteoarthritic cartilage. Restoration of the articular surface 
in vivo would then involve both repair, i.e. of the existing 
cartilage, and regeneration, i.e. of the surfaces completely 
devoid of cartilage. Suboptimal or scar tissue could be 
considered as repair tissue as stated in the definition above, 
however scar tissue in the end is not functional. As the 
current study involves pre-existent OA cartilage, we refer 
to our findings as “repair”.
